DRL also faces headwinds because of increasing competitive intensity in the generic market and exchange rate volatility.

Shares of Dr. Reddy's Laboratories Ltd. 500124 inched up 0.07% to 1,371.60 Indian rupees Thursday, on what proved to be an ...

Dr. Reddy’s, a global pharmaceutical company with ties to Louisiana, will close its Shreveport manufacturing plant and ...

Dr Reddy's share price rose nearly 4% after Nuvama Institutional Equities upgraded its rating to 'Buy' with a target of ...

Dr. Reddy’s Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate ...

Discover the Dr Reddys Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a ...

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...

After nabbing an FDA approval last summer for its T-cell lymphoma treatment Lymphir, Citius Oncology is eyeing strategic ...

HYDERABAD: Amid growing concerns and misconceptions about a potential outbreak of Human Metapneumovirus (HMPV), doctors emphasise the need for vigilance and a r ...

Join us on the Dr Reddys Stock Liveblog, your hub for real-time updates and comprehensive analysis on a prominent stock. Stay ...

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active ...

Dr. Reddy's Laboratories Ltd. 500124 shares rallied 1.47% to 1,370.60 Indian rupees Wednesday, on what proved to be an ...